to live to be 150 has
already been born.
— Aubry de Grey —
In our society, the quest for successful aging is becoming paramount. With increasing lifespans, the importance of enhancing the quality of life is critically important. According to the National Institute on Aging, by 2030 the population of people 65 and older worldwide will jump to 1 billion — one person out of every eight on the planet. While increased longevity represents one of humanity's great achievements, it is also creating a significant rise in aging-related conditions, including Frailty.
What is Frailty?
Frailty is a recognized, age-related clinical syndrome in which older adults lose strength and resilience, and are more vulnerable to overall decline, loss of independence, and mortality. It is estimated that about 7-16% of Americans over 65 have frailty and 25% of those over 85, representing a large portion of this growing population. These statistics are similar in other parts of the world especially countries with large aging populations.
Since the world population is living longer and requiring more medical care than ever before, quality of life in advanced years has decreased but medical costs have increased. This combination creates a tremendous impact on the healthcare system.
The Longeveron Solution
Longeveron's goal is to provide the first of its kind biological solution for aging. We are dedicated to developing safe cell-based therapeutics for Frailty and other age-related conditions to revolutionize the aging process and improve quality of life. Longeveron plans to initiate up to three proof of concept clinical trials in 2016 focusing on aging-related conditions including Frailty, Metabolic Syndrome and Alzheimer's Disease.
Longeveron has developed state-of-the-art manufacturing facilities at the Life Science & Technology Park (LSTP) in Miami, consisting of cGMP facilities, clean rooms, laboratory space and corporate headquarters. It consists of state-of-the-art laboratory, office, and retail space located on 10 acres in a HUBzone. LSTP is just a few blocks from the 153-acre University of Miami/Jackson Memorial Medical Center complex and the Miami VA Hospital, one of the largest medical centers in the country. The strategic location of Longeveron is thus ideally suited to access both patient and donor populations. Longeveron is currently adding 15,000 square feet of new manufacturing and administrative space to meet growing demands.
If you are interested in learning more about Longeveron or participating in a trial please fill out the form below or contact us.